What is the generic name of the MTP inhibitor used in this lipid-management context?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

What is the generic name of the MTP inhibitor used in this lipid-management context?

The main concept is how MTP inhibitors work to lower LDL-C. Microsomal triglyceride transfer protein (MTP) is needed to assemble and secrete apoB-containing lipoproteins in the liver and intestine. Blocking MTP reduces the production of VLDL and chylomicrons, which in turn lowers LDL cholesterol in the blood. Lomitapide is the generic name of the MTP inhibitor used in lipid-management contexts; it directly inhibits MTP, leading to decreased hepatic and intestinal production of atherogenic lipoproteins. The other options are not MTP inhibitors: statins reduce cholesterol synthesis by inhibiting HMG-CoA reductase, and niacin mainly affects HDL and triglycerides through different mechanisms. Lomitapide is especially used in difficult cases like homozygous familial hypercholesterolemia, often alongside diet and other lipid-lowering therapies, but it requires monitoring for liver toxicity and has important drug interaction considerations with CYP3A4 inhibitors.

The main concept is how MTP inhibitors work to lower LDL-C. Microsomal triglyceride transfer protein (MTP) is needed to assemble and secrete apoB-containing lipoproteins in the liver and intestine. Blocking MTP reduces the production of VLDL and chylomicrons, which in turn lowers LDL cholesterol in the blood. Lomitapide is the generic name of the MTP inhibitor used in lipid-management contexts; it directly inhibits MTP, leading to decreased hepatic and intestinal production of atherogenic lipoproteins. The other options are not MTP inhibitors: statins reduce cholesterol synthesis by inhibiting HMG-CoA reductase, and niacin mainly affects HDL and triglycerides through different mechanisms. Lomitapide is especially used in difficult cases like homozygous familial hypercholesterolemia, often alongside diet and other lipid-lowering therapies, but it requires monitoring for liver toxicity and has important drug interaction considerations with CYP3A4 inhibitors.

More practice questions